Meningitis is a broad term for any infection that inflames the protective lining around the brain and spinal cord. Meningitis B, often written as “MenB,” refers to one specific cause of that infection: a bacterial strain called Neisseria meningitidis serogroup B. Think of it this way: meningitis is the disease, and meningitis B is one particular version of it, defined by the exact bacterium responsible. That distinction matters because the causes, severity, and available vaccines differ dramatically depending on which type you’re dealing with.
Meningitis Has Many Causes
Dozens of different viruses, bacteria, and fungi can cause meningitis. They all produce inflammation in the same area, the membranes surrounding the brain and spinal cord, but the outcomes vary widely depending on what’s doing the infecting.
Viral meningitis is the most common form in adults and older children. Enteroviruses cause the majority of cases, though herpes simplex virus and the chickenpox/shingles virus can also be responsible. Viral meningitis is almost never life-threatening. Most people recover on their own within a couple of weeks without specific treatment.
Bacterial meningitis is far less common but far more dangerous. It can progress rapidly and become fatal within hours if not treated with antibiotics. The three bacterial families that cause most cases worldwide are meningococcal bacteria, pneumococcal bacteria, and Haemophilus influenzae. Among the meningococcal bacteria, there are several distinct serogroups, labeled by letter: A, B, C, W, and Y. Serogroup B is one of these.
What Makes Serogroup B Different
Meningococcal bacteria are categorized into serogroups based on the sugar coating on their outer surface. That coating determines how the immune system recognizes the bacterium and, critically, which vaccine can protect against it. Serogroup B has a coating that is chemically similar to molecules found on human nerve cells, which made it uniquely difficult to develop a vaccine against. Scientists couldn’t use the same approach that worked for serogroups A, C, W, and Y. Instead, MenB vaccines had to be designed using different proteins on the bacterium’s surface.
This is why there are two separate meningococcal vaccines rather than one that covers everything. The MenACWY vaccine protects against four serogroups. The MenB vaccine protects only against serogroup B. They are not interchangeable, and getting one does not protect you against the strains covered by the other.
Symptoms Are Nearly Identical
Serogroup B meningitis does not look meaningfully different from meningitis caused by other bacterial serogroups. The typical symptoms are fever, sudden severe headache, nausea, vomiting, sensitivity to light, neck stiffness, and altered mental state. In young infants, the signs are less specific: intense irritability, refusal to eat, and sometimes abnormally low body temperature rather than a fever.
At least half of patients with meningococcal disease develop a distinctive rash of small, dark, purplish spots under the skin. This rash does not fade when you press a glass against it, which is a well-known warning sign. Early symptoms often mimic a generic viral illness, making rapid recognition a challenge even for experienced clinicians. By the time the rash or neck stiffness appears, the infection may already be advanced.
Doctors identify the specific serogroup through lab tests on blood or spinal fluid, but treatment begins immediately with broad-spectrum antibiotics. Waiting for lab confirmation would waste critical time.
Who Is Most at Risk for MenB
Anyone can develop meningococcal disease, but certain groups face higher odds. Infants under one year old have the highest rates overall. In the United States, serogroup B is responsible for roughly 60% of meningococcal cases in children younger than five. Among older age groups, teenagers and young adults between 16 and 23 are at elevated risk, partly because the bacteria spread through close contact, shared living spaces like college dormitories, and respiratory droplets.
People with compromised immune systems also face greater risk. That includes anyone whose spleen has been removed or damaged (including people with sickle cell disease), anyone with a rare immune condition called complement component deficiency, and people taking certain medications that suppress part of the immune system. Microbiologists who regularly handle meningococcal bacteria in the lab are another recognized high-risk group.
Vaccine Schedules Differ
The MenACWY vaccine is a standard part of the childhood immunization schedule. All adolescents receive a dose at age 11 or 12, with a booster at 16 because protection fades over time. Children as young as two months old may receive it earlier if they have specific risk factors.
The MenB vaccine follows a different path. It is not universally recommended for all adolescents. Instead, the CDC recommends a shared decision-making conversation between the patient (or parent) and their healthcare provider to decide whether MenB vaccination makes sense. Two doses are given six months apart, with the preferred age range being 16 through 18, which lines up with the years of highest risk. For people with specific medical conditions or during a serogroup B outbreak, the vaccine is directly recommended starting at age 10.
Two MenB vaccine brands are approved in the United States: Bexsero and Trumenba. If you start a series with one brand, you need to finish with the same one.
Long-Term Effects of MenB Infection
Surviving meningococcal serogroup B disease does not always mean a full recovery. A study published in The BMJ found that one in three children who survived serogroup B meningococcal disease developed lasting problems that weren’t immediately obvious. These “hidden” effects included measurable drops in IQ (about 8 points lower on average compared to peers who never had the disease), hearing loss, and deficits in memory and executive function, the mental skills needed for planning, focus, and self-control.
About 36% of survivors developed those cognitive deficits, and in nearly one in ten, the problems were considered severely disabling. On the more visible end, 1% of children with serogroup B disease required limb amputations. The overall case fatality rate for meningococcal disease in the U.S. sits around 16%, meaning roughly one in six people who develop it do not survive.
The Key Distinction
“Meningitis” encompasses every infection of the brain’s protective lining, from mild viral cases that resolve on their own to life-threatening bacterial emergencies. “Meningitis B” narrows the focus to one specific bacterial culprit, serogroup B of Neisseria meningitidis, which requires its own dedicated vaccine and carries a significant risk of death or permanent complications. Understanding that distinction is especially relevant when reviewing your own or your child’s vaccination records, because protection against serogroups A, C, W, and Y does not extend to serogroup B.